Opendata, web and dolomites


Viral Vaccine Vectors in Personalized Medicine

Total Cost €


EC-Contrib. €






 VIVAVE project word cloud

Explore the words cloud of the VIVAVE project. It provides you a very rough idea of what is the project "VIVAVE" about.

people    options    viral    modified    hence    depot    slowly    profile    melanoma    versatile    antigen    iatrogenic    life    surveillance    aggressive    expensive    clinical    immunity    relapse    provides    disease    cells    elimination    replicate    vector    worldwide    nuclei    host    successful    levels    human    lasting    stimulate    free    aborted    patients    strike    rapid    residual    uniquely    establishes    exceedingly    latency    innocuous    culture    cancer    stage    therapy    millions    tumors    infected    survive    genes    replication    animal    counterparts    safe    release    maintained    sustained    pipeline    poorly    bout    humans    tumor    deterrence    blocking    decades    monitored    vaccine    relapses    promotes    fills    grows    time    virus    infection    neoplastic    generally    immune    active    faster    vectors    expressed    tissue    pathogens    lymphoma    condemned    released    minimal    combines    class    arising    therapies    few    grow    developers    vaccines   

Project "VIVAVE" data sheet

The following table provides information about the project.


Organization address
postcode: 38124

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙858 €
 EC max contribution 149˙858 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2018-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Melanoma and lymphoma are tumors that strike millions of people worldwide and require aggressive and expensive therapies. Numerous therapies are already being used or in the pipeline, yet all of them focus on the rapid elimination of the active neoplastic process. They do not provide options for long-term surveillance and deterrence of minimal residual disease, that is, of cancer relapse arising from the few tumor cells that survive the aggressive bout of therapy. Therefore, even patients considered cancer-free upon successful therapy are monitored over decades for potential relapses and condemned to a life of uncertainty. I propose to develop a novel class of versatile tumor vaccines for long-term surveillance of tumors based on a modified virus vector. Our modified viral vector combines an exceedingly safe profile with robust and long-lasting immunity. Several developers have focused on human virus vaccine vectors that grow poorly in tissue culture, and as human pathogens, present iatrogenic concerns. Our modified viral vector system grows faster in animal cells than human counterparts, but cannot replicate in human cells. Therefore, our vector system is generally considered innocuous for humans. The replication in human cells is aborted at the early stage of infection, but immediate-early genes are expressed at robust levels, and thus may stimulate immune responses. Our modified viral vector system establishes latency and is maintained for life in the nuclei of infected cells, where they release low levels of antigen for the life of the host. Thus, it provides a depot of antigen that is slowly released over time and promotes the uniquely strong and sustained immunity. Our approach is unique in its design to provide long-term immune surveillance of tumor cells, and thus in blocking relapses. Hence, we propose to develop a unique product that fills an important clinical need.


year authors and title journal last update
List of publications.
2019 Elham Beyranvand Nejad, Robert B. Ratts, Eleni Panagioti, Christine Meyer, Jennifer D. Oduro, Luka Cicin-Sain, Klaus Früh, Sjoerd H. van der Burg, Ramon Arens
Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection
published pages: , ISSN: 2051-1426, DOI: 10.1186/s40425-019-0500-9
Journal for ImmunoTherapy of Cancer 7/1 2019-07-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIVAVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIVAVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  


The Mass Politics of Disintegration

Read More